Livzon Pharmaceutical Group (HK:1513) has released an update.
Livzon Pharmaceutical Group’s subsidiary, Shanghai Livzon Pharmaceutical Manufacturing, has achieved a significant milestone as its Leuprorelin Acetate Microspheres for Injection successfully passed quality and efficacy consistency evaluation by the National Medical Products Administration. This approval enhances the company’s position in the generic drug market, potentially boosting investor confidence. Such developments could positively impact Livzon Pharmaceutical’s stock performance.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.
